# US 2023/0068388 A1 · Methods for increasing the diversity of monoclonal antibodies produced against an antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068388 A1
- Document ID: US20230068388A1
- Status: Published application
- Kind: A1
- Application number: 17/885,692
- Filed: 2022-08-11
- Published: 2023-03-02
- Earliest claimed: 2004-10-12
- Assignees: Acton Biotech Consulting
- Applicants: Acton Biotech Consulting
- Inventors: Dale Anthony Cumming
- Web page: https://patentgrep.com/patent/US20230068388A1

## CPC

- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- A01K 67/0276: Knock-out vertebrates
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 16/18: against material from animals or humans
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/3092: {against tumour-associated mucins}
- C12N 9/1048: {Glycosyltransferases (2.4)}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- A01K 2267/03: Animal model, e.g. for test or diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55583: {Polysaccharides}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods for increasing the diversity of monoclonal antibodies produced against an antigen. The methods of the invention utilize immunization of a murine host defective in one or more enzymes involved in a post-translational modification of a polypeptide or a modification of a lipid, wherein said modification is exposed on a cell surface. The invention also relates to monoclonal antibodies produced by these methods and which are not produced when a normal mouse is immunized with the same antigen. The invention further relates to compositions comprising these monoclonal antibodies, as well as to such monoclonal antibodies bound or conjugated to a toxin, a detectable marker or to a solid support.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of producing an antibody library that comprises an antibody that binds to an epitope on a molecule of interest, wherein the epitope is not present naturally in a wild-type host, the method comprising the steps of:
(a) immunizing a knockout host with an antigen that comprises the epitope present on said molecule of interest in a manner sufficient for said knockout host to develop antibodies against said epitope, wherein when the wild-type host is immunized with the antigen it does not produce an antibody that binds to the epitope, wherein said knockout host comprises a knockout mutation in an enzyme involved in post-translational glycosylation of a polypeptide;
(b) isolating splenocytes or B cells from said immunized host;
(c) extracting ribonucleic acid (RNA) from the isolated splenocytes or B cells; and
(d) generating an antibody library from the extracted RNA.

### Claim 22 (depends on 21)

The method of claim 21, wherein the library is a phage display library.

### Claim 23 (depends on 21)

The method of claim 21, wherein the library is a yeast display library.

### Claim 24 (depends on 21)

The method of claim 21 further comprising the step of amplifying the RNA by polymerase chain reaction (PCR).

### Claim 25 (depends on 21)

The method of claim 21, wherein the B cells are isolated from blood, bone marrow, or lymph node.

### Claim 26 (depends on 21)

The method of claim 21, wherein the splenocytes or B cells obtained in step (b) are immortalized.

### Claim 27 (depends on 26)

The method of claim 26, wherein the splenocytes or B cells are immortalized by viral infection or transduction.

### Claim 28 (depends on 27)

The method of claim 27, wherein the isolated splenocytes or B cells are fused with other cells.

### Claim 29 (depends on 21)

The method of claim 21, wherein the host is a non-human mammal.

### Claim 30 (depends on 21)

The method of claim 21, wherein the host is a genetically modified non-human animal comprising one or more human immunoglobulin sequences that encode an antibody gene.

### Claim 31

A method of producing RNA that encodes for an antibody that binds to an epitope that is not present naturally in a wild-type host, the method comprising the steps of:
(a) immunizing a knockout host with an antigen that comprises the epitope in a manner sufficient for said knockout host to develop antibodies against said epitope, wherein when the wild-type host is immunized with the antigen it does not produce an antibody that binds to the epitope, wherein said knockout host comprises a knockout mutation in an enzyme involved in post-translational glycosylation of a polypeptide; and
(b) amplifying RNA isolated from B cells of said immunized host by PCR.

### Claim 32 (depends on 31)

The method of claim 31, wherein the B cells are from blood, bone marrow, or lymph node.

### Claim 33 (depends on 31)

The method of claim 31 further comprising the step of generating an antibody library from the isolated RNA.

### Claim 34 (depends on 33)

The method of claim 33, wherein the library is a phage display library.

### Claim 35 (depends on 33)

The method of claim 33, wherein the library is a yeast display library.
